FY2022 Q3 Financial and R&D Update

ENHERTU Performance in Each Region (US, EU) Steady increase in product sales due to market penetration and additional indications Global product sales: FY2022 Q3 YTD results 139.7 Bn JPY (YOY +96.2 Bn JPY) 200.4 Bn JPY (YOY +135.0 Bn JPY) FY2022 forecast Daiichi-Sankyo US Product sales: FY2022 Q3 YTD results 99.8 Bn JPY (731 Mn USD) 141.6 Bn JPY (1,050 Mn USD) FY2022 forecast Indication: HER2+ BC 2L/3L, HER2 low BC (post-chemo), HER2+ GC 2L, HER2 mutant NSCLC 2L Market share status ➤ HER2+ BC 2L/3L: Maintaining No.1 new patient share HER2 low BC: Achieved No.1 new patient share HER2+ GC 2L: Maintaining No.1 new patient share HER2 mutant NSCLC 2L: Good uptake in the population Other progress ➤ Approved for HER2+ BC 2L and started promotion (May 2022) Classified as a category 1 preferred regimen for patients with tumors that are HER2 IHC 1+ or 2+ and ISH negative in NCCN*1 guidelines (Jun. 2022) Approved for HER2 low BC (post chemo) and HER2 mutant NSCLC 2L and started promotion (Aug. 2022) *1 NCCN: National Comprehensive Cancer Network Blue letters: updates from Q2 Europe Product sales: FY2022 Q3 YTD results 22.3 Bn JPY (163 Mn USD) FY2022 forecast 32.8 Bn JPY (243 Mn USD) Indication: HER2+ BC 2L/3L, HER2 low BC (post-chemo), HER2+ GC 2L Market share status ➤ HER2+ BC 2L: Increasing significantly in launched countries/regions (No.1 in France) ➤ HER2+ BC 3L: Maintaining No.1 new patient share Other progress (UK, France, Germany) ➤ Approved for HER2+ BC 2L and started promotion (Jul. 2022) ➤ Approved for HER2+ GC 2L and started promotion (Dec. 2022) Launched in Spain (Dec. 2022) Approved for HER2 low BC (post-chemo) and started promotion (Jan. 2023) >ENHERTU trastuzumab deruxtecan Ⓡ 13

View entire presentation